By Sree Roy
Paid for by YRT Limited
In the landscape of modern sleep medicine, few innovations have promised as much clinical precision as the Odds Ratio Product (ORP). Developed by the esteemed researcher Magdy Younes, MD, FRCP(C), PhD, ORP serves as a continuous, objective measure of sleep depth—a sophisticated metric that transcends the limitations of traditional, subjective sleep staging. Now, at 87 years old, Dr. Younes has launched a definitive initiative through YRT Limited to ensure his life’s work becomes a foundational pillar of sleep science. By opening access to ORP and its derivatives, Younes is racing against time to democratize a tool he believes is essential for the future of patient care.
The Genesis of a Metric: Understanding ORP
For decades, the standard for assessing sleep has relied on the American Academy of Sleep Medicine (AASM) manual—a system of visual scoring that segments sleep into discrete stages (N1, N2, N3, and REM). While functional, this method is inherently limited by human subjectivity and the inability to capture the "shades of gray" within sleep depth.
Dr. Younes, a titan in respiratory physiology and sleep research, sought to bridge this gap. The Odds Ratio Product is an EEG-derived metric that assigns a continuous value to sleep depth, ranging from 0 (deep, stable sleep) to 15 (wakefulness). Unlike traditional staging, which might classify a patient as being in "N2" for an entire hour, ORP tracks the subtle, moment-to-moment fluctuations in brain activity that dictate how restorative a patient’s sleep truly is.
Chronology: From Academic Pursuit to Market Realities
The journey of ORP has been marked by scientific brilliance and, eventually, a sobering lesson in the mechanics of medical commercialization.
The Early Development (1990s–2010s)
Dr. Younes spent the better part of his career dissecting the electroencephalogram to find mathematical correlations between EEG power spectral analysis and the physiological drive to sleep. His research moved from the lab bench to clinical validation, demonstrating that ORP could predict sleep stability and respiratory outcomes far more accurately than standard apnea-hypopnea indices (AHI).
The Cerebra Health Era (2015–2025)
ORP gained its first significant commercial exposure through Cerebra Health. The intent was to bring high-level diagnostics to the home sleep testing (HST) market. However, the business model faced significant headwinds. By bundling the ORP algorithm exclusively with a proprietary Type II home sleep testing device, the technology was tethered to a specific hardware ecosystem.
As the regulatory and reimbursement landscape for home sleep testing shifted, the lack of interoperability proved fatal to the model. In early 2025, Cerebra Health shuttered, leaving many in the research community concerned about the fate of the ORP metric.
The Pivot: YRT Limited (2025–Present)
Dr. Younes recognized that the failure of the commercial entity was not a failure of the science. The ORP metric remained, in his view, the most accurate tool available for sleep depth assessment. By founding YRT Limited, Younes has shifted his strategy: rather than forcing the market to adopt a specific hardware device, he is opening the ORP algorithm to the research community at large, regardless of the recording hardware used.
Supporting Data: Why ORP Matters
The implications of adopting ORP in clinical research are profound. Standard metrics like the AHI only tell us how often a patient stops breathing; they do not quantify the physiological impact of that breathing instability on sleep architecture.
Precision Medicine in Sleep
Research utilizing ORP has consistently shown that "stable" sleep is not a monolith. Patients with the same AHI may experience vastly different levels of sleep fragmentation, which ORP can identify. This allows clinicians to:
- Predict Treatment Response: Determine which patients are most likely to benefit from CPAP therapy versus those who might require mandibular advancement devices or surgical intervention.
- Identify Residual Symptoms: Explain why patients often report feeling unrefreshed despite having "normal" sleep studies.
- Quantify Drug Effects: Provide pharmaceutical researchers with a granular tool to measure the impact of hypnotics and sedatives on sleep consolidation.
The Nine Architectures of Sleep
Dr. Younes has categorized sleep into nine distinct "architecture types" based on ORP, ranging from highly restorative patterns to those characterized by chronic, low-level micro-arousals. This framework provides a new diagnostic language for sleep medicine, moving the field away from categorical labeling and toward a spectrum-based understanding of neurological health.
Official Stances and the YRT Limited Mission
The philosophy driving YRT Limited is one of accessibility. Dr. Younes is acutely aware that his time to see this technology fully integrated into clinical practice is limited. To accelerate adoption, YRT Limited is providing a streamlined pathway for investigators to integrate ORP into their studies.
A Commitment to Cost-Efficiency
In a move that distinguishes YRT from traditional medical technology firms, YRT Limited has adopted a "cost-only" pricing structure for research projects where fees are not otherwise waived. The company calculates charges based solely on the technical hours required to perform the sleep study scoring, ensuring that the financial barrier to entry for academic and clinical researchers is minimized.
"The goal is not profit; the goal is validation and utility," says a spokesperson for the YRT initiative. By removing the proprietary barriers that previously hindered ORP’s distribution, the team hopes to catalyze a wave of new studies that will confirm the metric’s utility across diverse patient populations, including those with insomnia, OSA, and neurodegenerative conditions.
Implications: The Future of Sleep Medicine
The "un-tethering" of ORP from hardware signifies a turning point in sleep medicine. As the industry moves toward digital biomarkers and AI-driven diagnostics, the ability to analyze legacy data—and data from any laboratory-grade polysomnogram—is critical.
The "Universal" Diagnostic Tool
Because YRT Limited is making the ORP algorithm available for Type I (in-lab) studies, it directly addresses the critique that previously limited its growth. In-lab sleep centers, which handle the most complex cases, can now apply ORP to their existing data workflows without needing to purchase proprietary hardware. This increases the likelihood that ORP will eventually be incorporated into the standard scoring guidelines of the AASM.
Empowering the Next Generation
Dr. Younes’ legacy is not merely the metric itself, but the data culture he is fostering. By providing access to the raw analytical framework, he is inviting a new generation of sleep scientists to test, challenge, and refine the ORP architecture.
For the thousands of patients suffering from undiagnosed sleep fragmentation, the widespread implementation of ORP could mean the difference between a lifetime of fatigue and a precise, targeted intervention. As Dr. Younes continues his work, the medical community is watching closely, recognizing that they are witnessing the final, vital chapter of a pioneer’s career—one that aims to leave the field of sleep medicine significantly more objective than he found it.
How to Engage
Interested investigators, sleep centers, and research institutions are encouraged to contact YRT Limited to discuss potential collaborations. Whether for retrospective analysis of large datasets or prospective clinical trials, the door is now open. To ensure that research projects are aligned with the mission of improving sleep diagnostics, investigators are invited to reach out via the YRT Limited contact page.
Please mention that you heard about the service through Sleep Review.
Conclusion: A Race for Impact
The story of Magdy Younes and the Odds Ratio Product is a testament to the resilience of scientific truth. While the market may fluctuate and commercial ventures may rise and fall, the underlying physiological discoveries remain. By choosing to prioritize the dissemination of his research over the retention of intellectual property, Dr. Younes is ensuring that his life’s work will serve as a lighthouse for the next generation of sleep researchers.
The validation of ORP is no longer a question of "if," but "when." With the new accessibility provided by YRT Limited, that "when" may be sooner than anyone expected, potentially ushering in an era of sleep medicine where the quality of one’s rest is as measurable, and as manageable, as the rhythm of one’s heart.
